Okrido (Prednisolone Sodium Phosphate)

Prednisolone Sodium Phosphate, the active ingredient in Okrido, is a corticosteroid presented as an oral formulation for systemic use. It is employed to reduce inflammation and modulate immune responses in a variety of acute and chronic conditions. GNH USA supplies Okrido as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Prednisolone Sodium Phosphate is a systemic glucocorticoid used to manage inflammatory and immune‑mediated disorders. - Severe allergic reactions: rapidly diminishes swelling, itching and airway obstruction. - Asthma exacerbations: decreases airway inflammation and improves breathing. - Rheumatoid arthritis: reduces joint pain, swelling and structural damage. - Inflammatory bowel disease (e.g., ulcerative colitis): controls mucosal inflammation and induces remission.

Prednisolone Sodium Phosphate may cause a range of adverse reactions, varying by dose and duration.

Common Side Effects: - Increased appetite and weight gain - Insomnia or mood swings - Elevated blood glucose levels - Gastrointestinal discomfort or ulceration - Fluid retention and mild hypertension

Serious or Rare Side Effects: - Adrenal insufficiency on abrupt discontinuation - Severe infections due to immunosuppression - Osteoporosis with long‑term use - Cataracts or glaucoma - Psychosis or severe mood disorders - Thromboembolic events

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for complications. - Assess infection risk: avoid use in uncontrolled systemic infections. - Monitor blood glucose: adjust antidiabetic therapy as needed. - Evaluate bone health: consider calcium/vitamin D supplementation for long‑term treatment. - Review psychiatric history: watch for mood changes or psychosis. - Check ocular health: periodic eye examinations are advised. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Prednisolone Sodium Phosphate can alter the pharmacokinetics or pharmacodynamics of several medicines.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase glucocorticoid exposure. - Live vaccines: risk of disseminated infection. - NSAIDs: heightened risk of gastrointestinal bleeding. - Anticoagulants (e.g., warfarin): enhanced anticoagulant effect. - Diuretics: increased potassium loss.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: possible hyperglycemia, require dose adjustment. - Antihypertensives: potential reduction in blood pressure control. - Non‑live vaccines: may diminish immune response. - Antifungals (moderate CYP3A4 inhibitors): monitor for increased steroid effects.